Recent Updates
Recently added Catalysts

Obsidian Therapeutics, Inc.

OBXFDA catalysts, PDUFA dates & pipeline intelligence
$12.14
▼ -0.42 · -3.34%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full OBX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
144.69 K
Value Traded
1.79 M
Short % Float
2.19%
Days to Cover
3.9
-11.01%Week
+2.18%1 Month
-30.42%3 Month

Cash Data

Unlock OBX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
753.95 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
424.35 M
Total Shares
61.73 M
Float Shares
54.12 M
Insiders
12.40%
Institutions
34.09%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout
amsokigene autoleucel (amsoki-cel)
non-small cell lung cancer (NSCLC)
Phase 1Cell TherapiesOncology
Unlock every OBX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

OBX Catalyst Timeline

Dated clinical, regulatory and corporate events for Obsidian Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Obsidian Therapeutics, Inc.

24Total events
5Upcoming
7Tier-1 (high impact)
2026 to 2028Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
amsoki-cel
T2Enrollment Complete
Subscribe to view catalyst details
amsoki-cel

Event history 15

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Poster Presentationamsoki-celPresentation
Updated amsoki-cel efficacy and pooled safety data presented in poster at SITC 2026
advanced melanomasource ↗
▲Publicationamsoki-celPresentation
Pooled Phase 1 and 1/2 results published in Nature Medicine
advanced melanomasource ↗
▲Full Resultsamsoki-celClinical Data
Updated amsoki-cel efficacy (67% ORR) and pooled safety data presented at SITC 2026
advanced melanomasource ↗
▲Oral Presentationamsoki-celPresentation
amsoki-cel data presented at SITC 2026 Annual Meeting
advanced melanomasource ↗
▲Additional Dataamsoki-celClinical Data
Updated efficacy data at RP2D: 67% ORR, mPFS 8.3 months, mDOR not reached
advanced melanomasource ↗
▲First Patient Dosedamsoki-celTrial
First patient enrolled in registration-enabling cohort of Agni-01 study
advanced melanomasource ↗
▲FDA Feedback Receivedamsoki-celFDA Meeting
FDA alignment obtained for registration-enabling cohort
advanced melanomasource ↗
▲Primary Endpoint Metamsoki-celClinical Data
Positive Phase 1/2 results: 67% ORR at RP2D
advanced melanomasource ↗
▲Accelerated Approval Pathwayamsoki-celDesignation
Single-arm trial design intended to support future BLA submission via accelerated approval
advanced melanomasource ↗
Unlock the full OBX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How OBX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-07amsokigene autoleucel (amsoki-cel, formerly OBX-115) Phase 1/2 data presentation Phase 1/2
Unlock all OBX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 81%
Micro Cap
(rank 587 of 725)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
OBX-115 Cell TherapiesNCT06060613Tumor SkinPhase 1/2 RECRUITING 254Jun 30, 2029
Unlock the OBX pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every OBX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
amsoki-cel advanced melanomaPhase 1/22026-11-12objective response rate: 67%; median progression free survival: 8.3 months; median duration of response: not yet reached; median study follow up: 14.3 monthsRead MoreObsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesRead More
Scroll for more · summaries link to the source press release
Unlock every OBX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock OBX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full OBX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in OBX for Q2 2026.
Unlock every fund holding OBX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in OBX
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see OBX ownership
Insider and institutional ownership, quarter by quarter.

OBX Short Interest

Shares sold short, counted twice a month.

2.19%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
+9.6% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
300.6K
Avg Daily Volume
the average used for days to cover
Unlock OBX short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock OBX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live OBX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock OBX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How OBX ranks across every disease it competes in

Competitive Position is a premium feature
See how OBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

OBX News

-OBX
Nov 12, 2026
OBXPhases
▼ -3.3%today

Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Obsidian Therapeutics reported positive updates on amsoki-cel for advanced melanoma, showing a 67% objective response rate and a median progression-free survival of 8.3 months. The company is currently enrolling patients in a registration-enabling cohort of the Phase 1/2 Agni-01 study, with topline data expected by the end of 2027. Additionally, Obsidian has a strong cash position of $324.4 million.

Read more →
-OBX
Nov 6, 2026
OBXConferences/Events
▲ +44.4%on this news

Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting

Obsidian Therapeutics reported positive results for amsoki-cel in advanced melanoma. The therapy achieved a 67% objective response rate, with significant durability of responses. Safety data showed no dose-limiting toxicities. Updated data will be presented at the SITC 2026 Annual Meeting, with further results expected by year-end 2027.

Read more →
-OBX
Oct 2, 2026
OBXConferences/Events

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

Obsidian Therapeutics has announced a poster presentation of updated data on amsoki-cel for patients with immune-checkpoint inhibitor-resistant advanced melanoma. This data is derived from both a Phase 1 single-center first-in-human study and a Phase 1/2 multicenter study. The presentation will take place at the SITC 2026 Annual Meeting.

Read more →
-OBX
Aug 5, 2026
OBXPhases
▼ -16.1%on this news

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

Obsidian Therapeutics has successfully enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study. This study evaluates amsoki-cel, an engineered tumor-infiltrating lymphocyte therapy, for treating advanced melanoma. The enrollment marks a crucial step towards potential regulatory approval for this innovative treatment.

Read more →
-OBX
Aug 3, 2026
OBXGeneral

Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million

Obsidian Therapeutics has completed its merger with Galera Therapeutics and raised $350 million through a private placement. The combined company will focus on advancing its engineered TIL cell therapies, particularly OBX-115, which is in clinical trials for solid tumors. The funding is expected to support operations through key clinical milestones until the second half of 2028.

Read more →
-OBX
May 21, 2026
OBXPhases

Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting

Obsidian Therapeutics announced promising Phase 2 results for OBX-115, an engineered TIL cell therapy for advanced melanoma. The therapy demonstrated a 67% objective response rate, including two complete responses, with a favorable safety profile. The results will be presented at the 2026 ASCO Annual Meeting, highlighting OBX-115's potential as a viable treatment option for patients with difficult-to-treat melanoma.

Read more →
-OBX
Apr 21, 2026
OBXPhases

Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting

Obsidian Therapeutics will present Phase 2 clinical data for OBX-115, an engineered TIL cell therapy, at the 2026 ASCO Annual Meeting. The study focuses on patients with advanced melanoma who have not responded to immune checkpoint inhibitors. The presentation is scheduled for June 1, 2026, and aims to highlight the therapy's potential benefits.

Read more →
-OBX
Apr 15, 2026
OBXGeneral

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Galera Therapeutics and Obsidian Therapeutics have announced a merger agreement to form a new company, Obsidian Therapeutics, Inc., along with a $350 million private placement financing. The merger aims to leverage Obsidian's engineered TIL cell therapies and is expected to fund operations into 2028. The transaction is anticipated to close by Q3 2026, pending stockholder approval.

Read more →
-OBX
Jan 12, 2026
OBXGeneral

Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer

Obsidian Therapeutics has appointed Julie Feder as Chief Financial Officer. With over 20 years of experience in strategic finance, Feder's expertise is expected to support the company's clinical development of OBX-115, an engineered TIL cell therapy. The appointment comes at a crucial time as the company progresses towards registration-enabling trials.

Read more →
-OBX
Jun 2, 2025
OBXPhases

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Obsidian Therapeutics presented positive Phase 1 clinical data for OBX-115 at the 2025 ASCO Annual Meeting. The study involved 11 patients with advanced melanoma who were resistant to immune checkpoint inhibitors. The novel therapy, which utilizes engineered TIL cells, achieved an overall response rate of 67%.

Read more →
-OBX
Apr 28, 2025
OBXConferences/Events

Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting

Obsidian Therapeutics announced the presentation of preclinical data from its cytoDRiVE platform at the ASGCT Annual Meeting 2025. The data showcases novel applications for regulating therapeutic proteins, including a new approach using artificial transcription factors. The lead program, OBX-115, aims to treat patients with advanced melanoma by leveraging pharmacologically regulatable IL15.

Read more →
-OBX
Apr 25, 2025
OBXConferences/Events

Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

Obsidian Therapeutics announced the presentation of three abstracts at the AACR Annual Meeting 2025, showcasing advancements in their engineered cell and gene therapies. Highlights include updates on the Agni-01 trial and preclinical data from the cytoDRiVE platform, which enhances IL12 expression for improved tumor control. The findings suggest potential benefits for patients with advanced solid tumors.

Read more →
-OBX
Apr 23, 2025
OBXConferences/Events

Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting

Obsidian Therapeutics announced two presentations at the 2025 ASCO Annual Meeting, including an oral presentation of Phase 1 results from the Agni-01 study of OBX-115, an engineered TIL cell therapy for patients with ICI-resistant advanced melanoma. The presentations will take place from June 1-3, 2025, in Chicago.

Read more →

About Obsidian Therapeutics, Inc.

Cambridge, MA obsidiantx.com
Headquarters1030 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02138
BIOPHARMAWATCH ELITE
Trade the next OBX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime